Brind.

Ian Clark served as CEO of Genentech and was appointed to the BioMarin Pharmaceutical Board of Directors.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Hoffmann-La Roche BioMarin Pharmaceutical Ian Clark

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
BioMarin Pharmaceutical
American company
- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Sun 20:41
Ian Clark
researcher (ORCID 0000-0001-8673-5603)

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 1PR NewswireBioMarin Announces Appointment of Ian T. Clark to Board of Directors SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appoin